Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
SanBio Co ( (JP:4592) ) has shared an announcement.
SanBio Company Limited reported its consolidated financial results for the three months ended April 30, 2025, showing a net loss of ¥1,531 million, a significant increase from the previous year’s loss of ¥144 million. The company’s financial position showed an increase in total assets but a decrease in equity ratio, indicating potential challenges in financial stability. Despite these losses, SanBio continues to focus on its long-term strategic goals in the biotechnology sector.
The most recent analyst rating on (JP:4592) stock is a Hold with a Yen1400.00 price target. To see the full list of analyst forecasts on SanBio Co stock, see the JP:4592 Stock Forecast page.
More about SanBio Co
SanBio Company Limited is a biotechnology company listed on the Tokyo Stock Exchange, focusing on regenerative cell therapies. The company is involved in developing innovative treatments aimed at addressing unmet medical needs, primarily in the field of neurological disorders.
Average Trading Volume: 5,613,796
Technical Sentiment Signal: Buy
Current Market Cap: Yen265B
Learn more about 4592 stock on TipRanks’ Stock Analysis page.